UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest reported): ~~December~~February 185, ~~2024~~2025

Novo Integrated Sciences, Inc.

(Exact name of registrant as specified in its charter)

Nevada	001-40089	59-3691650
(State or other jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification Number)

11120 NE 2nd Street, Suite 100, Bellevue, WA 98004

(Address of principal executive offices)

(206) 617-9797

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on which Registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02. ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

OnAs ~~December~~previously 18disclosed, on November 7, 2024, ~~Novo~~Robert Mattacchione resigned as Chief Executive Officer of Novo Integrated Sciences, Inc. ~~issued~~(the a“Company”), ~~press~~effective ~~release~~90 ~~announcing~~days ~~its~~following ~~financial~~the ~~results~~notification ~~for~~date ~~the~~(i.e. ~~fiscal~~effective ~~year~~February ~~ended August~~5, 312025). Thereafter, ~~2024~~on February 5, 2025, the Company and Mr. AMattacchione ~~copy~~agreed to extend the effective date of ~~this~~Mr. ~~press~~Mattacchione’s resignation ~~release~~to isFebruary ~~attached~~20, ~~hereto~~2025 asin ~~Exhibit~~order ~~99.1~~to ~~and~~allow ~~incorporated~~a ~~herein~~more byefficient ~~reference.~~transition ~~The~~for ~~information~~the ~~contained in~~Company and to appropriately address the ~~website~~vacant Chief isExecutive ~~not~~Officer aposition ~~part~~ensuring the least amount of ~~this~~disruption ~~Current~~as ~~Report~~a onresult ~~Form~~of ~~8-K~~the executive change.

~~The~~Thereafter, ~~information~~Mr. ~~furnished~~Mattacchione ~~pursuant~~intends to ~~this~~continue ~~Item~~to ~~2.02,~~serve ~~including~~as (i) the ~~information~~Company’s ~~contained~~Chairman inof ~~Exhibit~~the ~~99.1~~Board, ~~is “furnished”~~ and ~~not~~ ~~“filed”~~(ii) ~~for~~Chairman ~~purposes~~ of ~~Section~~Novo 18Healthnet ofLimited, a ~~the~~wholly ~~Securities~~owned ~~Exchange~~subsidiary ~~Act~~ of ~~1934 (~~the ~~“Exchange~~Company. ~~Act”)~~Mr. ~~or otherwise~~Mattacchione’s ~~subject~~resignation towas ~~the liabilities of that section. Such information shall~~ not bea ~~incorporated~~result byof ~~reference~~any indisagreement ~~another~~with ~~filing under~~ the ~~Exchange Act~~Company oron ~~the~~any ~~Securities~~matter ~~Act~~relating ~~of 1933, as amended, except~~ to the ~~extent~~Company’s ~~such~~operations, ~~other~~policies or ~~filing specifically incorporates such information by reference~~practices.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by the registrant on December 18, 2024.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Novo Integrated Sciences, Inc.
Dated: December 18, 2024	By:	/s/ Robert Mattacchione
Dated: February 11, 2025	By:	/s/ Robert Mattacchione
		Robert Mattacchione
		Chief Executive Officer

Filing Compare · Novo Integrated Sciences, Inc.